Fred Hutch Joins CERo Therapeutics Clinical Trial

The Seattle center joins a Phase 1 study testing the safety of the experimental CER-1236 therapy for blood cancers.

Updated on Oct. 26, 2026 in Biotech

Modern, sunlit laboratory research corridor with glass walls and clean architectural lines in a neutral color palette.
Fred Hutch Cancer Center has joined a multicenter Phase 1 clinical trial to test the safety of CERo Therapeutics’ experimental therapy CER-1236. AI Illustration. Upload story photo >

Live Poll

Is the pace of progress in developing new cancer treatments improving in your country?

CERo Therapeutics has activated the Fred Hutch Cancer Center in Seattle as a clinical site for its ongoing Phase 1/1b CERTAIN-T study. The multicenter trial evaluates the safety and tolerability of the experimental drug CER-1236 in patients.

Why it matters

The addition of a major research hub like Fred Hutch expands the testing footprint for CER-1236, an investigative therapy targeting challenging conditions like AML, MDS, and myelofibrosis. Ongoing trials are essential to determine the viability of this treatment approach for patients with limited options.

In the first two cohorts, six patients completed the 28-day dose-limiting toxicity assessment with no observed immune effector cell-associated neurotoxicity or cytokine release syndrome. One refractory AML patient proceeded to stem cell transplant 71 days after infusion.

The players

CERo Therapeutics

This biotechnology company is developing novel therapies for cancer and is based in South San Francisco, California.

Fred Hutch Cancer Center

This Seattle-based research and treatment facility is a major hub for oncology care and clinical investigations.

Jacob Appelbaum

He serves as the principal investigator for the clinical trial site located at the Fred Hutch Cancer Center.

The details

The CERTAIN-T study is an open-label trial assessing the pharmacokinetics and preliminary clinical activity of CER-1236. Researchers at the Seattle-based site will conduct these evaluations under the guidance of local investigative teams.

Timeline

  1. The company reported safety profile findings in June 2026.

  2. Fred Hutch Cancer Center was activated as a clinical trial site on October 26, 2026.

The Tech Race

The CERTAIN-T clinical trial protocol includes MDS and myelofibrosis, defining the current scope of diseases targeted by this therapeutic study. This site activation extends the research program as it moves through its initial Phase 1 evaluation stages.

This development increases access to experimental treatment options for local patients suffering from refractory blood cancers. Participants in the study will undergo rigorous monitoring to ensure drug safety and inform the future clinical trajectory of the therapy.

The takeaway

Early data from the first two patient cohorts show no immediate signs of severe immune toxicity. Continued clinical observation will be necessary to establish the broader therapeutic potential of the CER-1236 infusion.

Further reading

For more information on regional clinical research initiatives, visit the Biotech section.

Live Poll

Is the pace of progress in developing new cancer treatments improving in your country?